Palbociclib requires medical supervision because it can produce clinically significant blood-count abnormalities, pulmonary toxicity and reproductive risks.
Neutropenia
Neutropenia is a major warning associated with IBRANCE. CBCs should be checked before treatment, at the start of each cycle, on Day 15 of the first two cycles and as clinically indicated.
Patients should promptly report fever or other possible infection symptoms.
Interstitial lung disease and pneumonitis
Severe, life-threatening or fatal ILD/pneumonitis has been reported. New or worsening respiratory symptoms require clinical evaluation. Current labeling recommends interruption when ILD/pneumonitis is suspected and permanent discontinuation for severe cases.
Infection
Suppression of neutrophils can increase infection risk. Fever during treatment should not be ignored.
CYP3A interactions
Palbociclib is metabolized substantially through CYP3A pathways. Current labeling advises avoiding strong CYP3A inhibitors and strong CYP3A inducers. Strong CYP3A inhibitors can increase palbociclib exposure, while strong inducers can decrease exposure.
A medication review should include prescription drugs, over-the-counter products and herbal preparations.
CYP3A substrates
Palbociclib can affect exposure of sensitive CYP3A substrates with narrow therapeutic indices. Appropriate medication review is therefore important.
QT considerations
Current clinical pharmacology data indicate that palbociclib did not produce a large QTc effect at the labeled 125 mg schedule in the evaluated population. This does not eliminate the need for clinicians to consider the overall cardiac and medication profile of an individual patient.
Pregnancy
Palbociclib can cause fetal harm. Females of reproductive potential should use effective contraception during treatment and for at least 3 weeks after the last dose according to current U.S. labeling.
Lactation
Current U.S. labeling advises patients not to breastfeed during IBRANCE treatment and for 3 weeks after the final dose.
Male reproductive considerations
Current labeling advises male patients with partners of reproductive potential to use effective contraception during treatment and for at least 3 months after the last dose. Palbociclib may also affect male fertility.
Surgery and other treatment considerations
Treatment planning around surgery, severe infection, significant blood-count abnormalities or other major clinical events should be coordinated with the treating healthcare team.